Mergers & Acquisitions ·
SEC declares effective Zoar Limited's registration for proposed merger with Impact Biomedical
IBOImpact Biomedical Inc.
Impact Biomedical Inc. announced that the U.S. Securities and Exchange Commission declared effective the Form F-4 registration statement filed by Zoar Limited (f/k/a Dr Ashleys Limited) on October 23, 2026, marking a significant milestone toward closing their proposed business combination. The definitive proxy statement/prospectus was mailed to stockholders on the same date. Impact’s special meeting of stockholders is scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time to vote on the merger and other related matters. Upon closing, the combined entity is expected to operate as Zoar Limited and trade on NYSE American under the ticker symbol “ZOAR,” subject to listing approval. Completion remains subject to stockholder approval, NYSE American listing approval, and satisfaction of other closing conditions. Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness.